Q3 2024 Earnings Summary
- Nevro's launch of HFX AdaptiveAI, an AI-powered spinal cord stimulation (SCS) therapy that personalizes treatment using over 100 million data points, reduces patient burden by decreasing charging frequency from once per week to six times per year. This innovation improves operational efficiency by reducing the need for reprogramming visits and staff involvement, potentially driving adoption and revenue growth while lowering costs.
- The company has achieved significant cost reductions of over $30 million annually, enhancing profitability and cash flow. By strategically reinvesting in key areas like direct-to-consumer advertising and commercial execution—areas already showing positive impacts on trial volumes—Nevro is positioned to drive future revenue growth.
- Nevro is focusing on innovation and diversification by committing to research and development projects with clear return on investment. Expanding their product portfolio beyond SCS therapy, including offerings like SI joint fusion, and entering new established markets in pain management can open additional revenue streams and support long-term growth.
- The company experienced a significant decline in U.S. spinal cord stimulation trial procedures, down approximately 15.2%, indicating potential future revenue challenges.
- Cost-cutting measures, including reductions in direct-to-consumer advertising and headcount, have led to decreased sales, and while DTC advertising spend is being increased again, the benefits are not expected until the second half of 2025, potentially prolonging revenue weakness.
- The company's research and development spending decreased by about one-third, reaching the lowest levels since 2017 (excluding COVID period), which may negatively impact future innovation and growth prospects.
| Topic | Previous Mentions | Current Period | Trend |
|---|---|---|---|
Consistent focus on cost-cutting measures and restructuring | Mentioned each quarter (Q4 2023 , Q1 2024 , Q2 2024 ) with over $25M in 2024 savings and $30M+ in annual run-rate savings. | Still emphasized as a core strategy, resulting in $30M+ annual run-rate savings and $25M in 2024 savings. | Continues to be a major focus with disciplined OpEx management. |
Progress and new product launches in SCS therapy | Repeatedly highlighted (Q4 2023 , Q1 2024 , Q2 2024 ) showcasing HFX iQ rollouts and next-generation SCS development. | Continued emphasis on cutting-edge SCS advancements, including next-generation devices and EU expansion. | Ongoing innovation and AI integration bolster competitive positioning. |
Painful diabetic neuropathy (PDN) opportunities | Underpenetrated market (Q4 2023 , Q1 2024 , Q2 2024 ) with <1% penetration and strong clinical evidence driving growth. | Remains a focus; new data show long-term improvements in pain intensity and potential HbA1c reductions for PDN patients. | Continued potential in a large untapped market. |
SI joint fusion as a growth and diversification avenue | Emerged in Q4 2023 , continued in Q1 2024 , Q2 2024 as a key diversification strategy. | Reinforced as a ramping business with positive physician feedback and biomechanical advantages (Nevro1 system). | Expected to contribute meaningfully starting 2025, part of broader growth strategy. |
Revenue guidance adjustments and concerns | Addressed each period: Q4 2023 , Q1 2024 , Q2 2024 with downward revisions in Q2 and cautious outlook. | Maintained full-year revenue guidance at $400M–$405M, citing market headwinds but stable stance. | Remains cautious; no further reduction in guidance this quarter. |
Competitive pressures in the SCS market | Noted in Q4 2023 and Q2 2024 , affecting trial volumes and market share. | Continues to face stiff competition, impacting U.S. SCS trial procedures (down 15.2%). | Persistent challenge; Nevro aims to counter with commercial execution and new launches. |
Strategic review and potential M&A activities | Introduced in Q2 2024 with no specific outcomes or timetable announced. | No mention in Q3 2024. | Topic not revisited; no updates on strategic review. |
Costa Rica manufacturing facility’s impact on margins | Previously cited as driving cost efficiencies (Q4 2023 , Q1 2024 , Q2 2024 ). | Not discussed in Q3 2024. | No new updates on facility impact this quarter. |
New AI-driven technologies like HFX AdaptiveAI | No prior mention in Q4 2023, Q1 2024, or Q2 2024. | Introduced as an AI-powered solution reducing patient calls, reprogramming visits, and accelerating relief. | Newly emerged technology with potential to enhance patient outcomes and efficiency. |
Declining trialing activity for SCS and effect on revenue | Cited in Q1 2024 and Q2 2024 as lowering near-term SCS sales and influencing guidance. | Continues to fall (15.2% decrease) amid competitive and market pressures, impacting future SCS revenues. | Ongoing concern potentially delaying revenue recovery. |
-
Revenue Growth Amid Cost Cuts
Q: How will you grow revenue in 2025 despite expense cuts?
A: We believe that by focusing on investments that drive revenue, like increasing our direct-to-consumer (DTC) spend and leveraging AdaptiveAI technology, we can grow revenue even with reduced expenses. We're confident that our actions will reverse the trial decline and close the gap experienced in Q3, and AdaptiveAI allows us to grow without needing to add a one-to-one ratio of personnel. -
R&D Spending Reduction
Q: How do you balance cost cuts with future innovation?
A: We are prioritizing projects with clear return on investment and focusing on investments that drive future growth. While R&D spend decreased by about one-third, we are protecting investments that generate ROI and continue to fund meaningful clinical trials. -
Decline in U.S. Trials
Q: Can you elaborate on the 15% decline in U.S. trials?
A: The decline is due to factors like competitive pressure and reduced DTC spending. We turned down DTC earlier in 2024, which impacted trials, but as we increase DTC spend, we're already seeing trial volumes return. Also, replacements are growing, which don't require trials, affecting the trial numbers but not revenue. -
Impact of DTC Spending Adjustments
Q: What is the effect of adjusting DTC spending?
A: Reducing DTC spend led to a decline in patient leads and trials after several months. Upon increasing DTC spend in mid-third quarter, we're seeing patient flow return, but it takes 4–6 months for patients to move from consultation to trial. We expect improvements by the second half of 2025. -
Confidence in Cost Cuts
Q: Are you confident you haven't cut too deep into muscle?
A: Yes, we believe we got about 90% of the cost reductions right. The main area we adjusted was DTC spending, which we've corrected. We're investing in areas that drive revenue and profit, and focusing on efficiency, including leveraging AdaptiveAI and our Costa Rica operations. -
AdaptiveAI Benefits and Rollout
Q: How will AdaptiveAI impact efficiency and growth?
A: AdaptiveAI personalizes therapy and reduces the need for patient visits and reprogramming. Early results show a 40% reduction in patient visits and 50% reduction in call time compared to previous versions. This allows us to grow without adding proportional costs. -
Sales Force Expansion
Q: What's the plan for U.S. sales force dynamics?
A: We are promoting associate sales reps who have been in the field for 1.5 years to take on their own territories. These reps are familiar with the physicians and areas, enabling effective expansion without significant added cost. -
Versa Integration Progress
Q: How is the integration of Versa progressing?
A: We are still in the integration process, building necessary infrastructure and training physicians. The progress is aligning with our expectations, and we anticipate a more meaningful impact as we head into 2025. -
R&D Focus Areas
Q: What areas were affected by R&D cuts?
A: We've focused R&D on projects with clear ROI. Some clinical trials have completed, reducing spend in those areas. We continue to invest in diversifying our product portfolio and developing next-generation devices like AdaptiveAI. -
AdaptiveAI's Impact on Battery Life
Q: How does AdaptiveAI improve patient experience?
A: AdaptiveAI enables us to personalize therapy, reducing energy use of the battery. Patients may now only need to charge their devices six times per year, significantly decreasing the burden of charging.
Research analysts covering NVRO.